ZVRA
ZEVRA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.17
+8.87%Nov 3, 2026, 23:50 UTC
ZEVRA THERAPEUTICS, INC. reported quarterly earnings of $0.18 per share, compared with a loss of $0.01 per share a year earlier.
Source:Nov 3, 2026, 21:05 UTC
ZEVRA THERAPEUTICS, INC. reported $37.8 million in net revenue for the third quarter of 2026, including $34.0 million from MIPLYFFA.
Source:Oct 20, 2026, 11:30 UTC
Zevra Therapeutics announced that it will release its third-quarter 2026 corporate and financial results after market close on November 3, 2026, and host a conference call and audio webcast at 4:30 p.m. ET that day.
Source:Aug 6, 2026, 01:37 UTC
Zevra Therapeutics reported Q2 2026 earnings of $0.25 per share, surpassing the Zacks Consensus Estimate of $0.08 per share, and compared to $1.21 per share a year ago.
Aug 3, 2026, 11:30 UTC
Zevra Therapeutics announced the publication of four-year real-world data from its U.S. Early Access Program evaluating MIPLYFFA (arimoclomol) in Niemann-Pick Disease Type C (NPC).
Source:Jul 24, 2026, 11:30 UTC
The CHMP of the EMA adopted a negative opinion on the Marketing Authorization Application for arimoclomol for Niemann-Pick disease type C, and Zevra Therapeutics plans to request a re-examination.
Jun 11, 2026, 12:30 UTC
Zevra Therapeutics' Chief Medical Officer Adrian Quartel is stepping down effective July 3, 2026, due to personal reasons.
Source: